ArticleRadiation oncology (London, England)2021
Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study.
Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Combination of immune checkpoint inhibitors and radiotherapy for bone metastases induces an abscopal effect and improves outcomes in non-small cell lung cancer.Oncology letters · 2025Article
- Article
- Predictive Factors for Failed Nonsurgical Management of Long Bone Metastasis and Myeloma.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- High Fracture Risk of Femoral Bone Metastasis Treated with Palliative Radiotherapy in Recent Years.Current oncology (Toronto, Ont.) · 2024Article
- Prognostic assessment of patients with bone metastatic renal cell cancer treated with palliative radiotherapy.Oncology letters · 2024Article
- The role of spine stereotactic radiosurgery for patients with breast cancer metastases.Journal of neuro-oncology · 2024Article
- Advanced esophageal cancer with bone metastases: Prognostic biomarkers and palliative treatment.Heliyon · 2024Review
- Dosimetric evaluation of a spinal cord dose-limiting 3D-CRT technique for radiotherapy of spinal metastases.Journal of applied clinical medical physics · 2023Article
- Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study.Oncology letters · 2023Article
- Factors affecting local control of bone metastases from radioresistant tumors treated with palliative external beam radiotherapy.Discover oncology · 2023Article
- Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a Challenge.Biomedicines · 2023Article
- Factors Affecting Survival and Local Control in Patients with Bone Metastases Treated with Radiotherapy.Medical sciences (Basel, Switzerland) · 2023Article
- Local control after palliative external beam radiotherapy for bone metastases in patients with favorable prognosis.Molecular and clinical oncology · 2022Article
- Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Bushen Hugu Decoction in the Treatment of Malignant Tumor Bone Metastases.BioMed research international · 2022Article
- Changes in Spinal Instability After Conventional Radiotherapy for Painful Vertebral Bone Metastases.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone metastases according to the patient's prognosis. To establish individualized EBRT for bone metastases, we investigated factors that affect the local control (LC) of bone metastases.
methodsBetween January 2010 and December 2019, 536 patients received EBRT for 751 predominantly osteolytic bone metastases. LC at EBRT sites was evaluated with a follow-up computed tomography. The median EBRT dose was biologically effective dose (BED
resultsThe median follow-up time and median time of computed tomography follow-up were 11 (range 1-123) months and 6 (range 1-119) months, respectively. The 0.5- and 1-year overall survival rates were 73% and 54%, respectively. The 0.5- and 1-year LC rates were 83% and 79%, respectively. In multivariate analysis, higher age (≥ 70 years), non-vertebral bone metastases, unfavorable primary tumor sites (esophageal cancer, colorectal cancer, hepatobiliary/pancreatic cancer, renal/ureter cancer, sarcoma, melanoma, and mesothelioma), lower EBRT dose (BED
conclusionsRegarding tumor-related factors, primary tumor sites and the sites of bone metastases were significant for the LC. As for treatment-related factors, lower EBRT doses (BED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.